Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a therapy that induces closure and healing of fistulas in a greater percentage of patients than Centocor/Schering-Plough/Mitsubishi Tanabe's Remicade (infliximab) does, would earn a 30 percent patient share in the treatment of Crohn's disease, according to surveyed gastroenterologists.
The new report entitled Crohn's Disease: Physicians Seek Drugs That Treat Fistulizing Disease More Effectively than Infliximab finds that surveyed gastroenterologists indicated that they would prescribe Centocor/Janssen-Cilag's ustekinumab to 30 percent of their patients with Crohn's disease. As a result, ustekinumab is forecasted to earn a 5.4 percent patient share of the U.S. Crohn's disease market in 2012.
The report also finds that UCB's Cimzia will earn Decision Resources' proprietary clinical gold standard ("clinical gold standard") status for the treatment of Crohn's disease by 2011 as interviewed gastroenterologists indicate that Cimzia's efficacy and delivery profiles are superior to those of the current clinical gold standard, Abbott/Eisai's Humira. Although surveyed gastroenterologists indicated that Cimzia has advantages in efficacy and delivery, the therapy may be associated with more minor side effects when compared to Humira.
"Interviewed gastroenterologists report that Cimzia's pegylated formulation may prolong the drug's effect, resulting in a slightly more effective maintenance therapy with a superior maintenance dosing schedule in comparison to Humira," said Kathryn Benton, analyst at Decision Resources. "As a result, we forecast Cimzia to replace Humira as the clinical gold standard because of its incremental advantage in delivery and maintenance of clinical remission."
About the Report
Crohn's Disease: Physicians Seek Drugs That Treat Fistulizing Disease More Effectively than Infliximab is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial end points to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market share, patient share, and price-per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.
The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.
About Decision Resources
Decision Resources, Inc. (www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
For more information, contact: Elizabeth Marshall Decision Resources 781-296-2563 email@example.com
First Call Analyst:
SOURCE: Decision Resources Inc.
CONTACT: Elizabeth Marshall of Decision Resources, +1-781-296-2563
Web site: http://www.decisionresources.com/